Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug
Jan 23 (Reuters) – Puma Biotechnology Inc said on Tuesday a European regulatory panel indicated it was unlikely to provide a positive opinion on the company’s breast cancer drug, sending its shares down 30 percent. The setback comes six months after the U.S. Food and Drug Administration …